What is the clinical evidence from this study?

Study design: Cohort. Population: Type 2 diabetes mellitus and atrial fibrillation. Intervention: SGLT2 inhibitors. Primary outcome: Atrial fibrillation recurrence.

February 28, 2026Open Access

Correction: Effect of SGLT2 inhibitors on atrial fibrillation recurrence after catheter ablation in patients with type 2 diabetes in the United States: a TriNetX database study

Key Result

SGLT2 inhibitors were evaluated for their effect on atrial fibrillation recurrence in a study for which this article provides a correction regarding the specific TriNetX database used.

Study Design

Type

Cohort

Multicenter

Yes

Structured PICO

Do SGLT2 inhibitors reduce atrial fibrillation recurrence in adults aged 18-80 years with type 2 diabetes mellitus who underwent catheter ablation for atrial fibrillation?

Population

Adults aged 18–80 years with type 2 diabetes mellitus (T2DM) who underwent catheter ablation for atrial fibrillation (AF) between 2013 and 2024

Intervention

SGLT2 inhibitors

Outcome

Atrial fibrillation recurrence

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Khan et al. (Mon,) conducted a cohort in Type 2 diabetes mellitus and atrial fibrillation. SGLT2 inhibitors was evaluated on Atrial fibrillation recurrence. SGLT2 inhibitors were evaluated for their effect on atrial fibrillation recurrence in a study for which this article provides a correction regarding the specific TriNetX database used.

synapsesocial.com/papers/6a025a479cddff7633412ae0 https://doi.org/https://doi.org/10.1007/s10840-026-02268-z